1 October 2018 - What payer wouldn’t want to ensure that they pay for value when buying drugs? If the emerging trend in the US towards value-based contracting continues many more may be able to do so.

VBC deals see payers only pay when drugs meet agreed outcomes, getting a payback when they don’t, and Massachusetts-based not-for-profit health services company Harvard Pilgrim is seen as a trail blazer for striking value-base contracting (VBC) in the US.

Those tracking this trend at Stisali put them ahead of other US payers in striking the deals with pharma companies, with 15 VBCs in place according to a rare glimpse of spend Harvard Pilgrim published on the 24 August 2018.

Read Pharmaphorum article